You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 849 NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
849 NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model
Free

Authors

Citation

Phoon YP, Kai K, Wolfarth A, et al
849 NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0849

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.